drugset / Trial / NCT00348361

Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

NCT00348361

Phase 1 Completed 48 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.

Timeline

Start
2005-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified

Indications